|
1
|
Mortalidad por cáncer en Espana. 2005,
www.aecc.esurisimplewww.aecc.es.
|
|
2
|
Crist DW and Cameron JL: The current
status of the Whipple operation for periampullary carcinoma. Adv
Surg. 36:59–152. 1992.
|
|
3
|
Redston MS, Caldas C, Seymour AB, Hruban
RH, da Costa L and Yeo CJ: p53 mutations in pancreatic carcinoma
and evidence of common involvement of homocopolymer tracts in DNA
microdeletions. Cancer Res. 54:3025–3033. 1996.PubMed/NCBI
|
|
4
|
Garcia JF, Camacho FI, Morente M, Fraga M,
Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T,
Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre Mj, Mollejo
M, Saez AI, Sanchez L and Piris MA; Spanish Hodgkin’s Lymphoma
Study Group. Hodgkin’s and Reed-Stenberg cells harbor alterations
in the major tumor suppressor pathways and cell-cycle checkpoints:
analyses using tissue microarrays. Blood. 101:681–689. 2003.
|
|
5
|
Googins M, Achutte M, Lu J, Moskaluk CA,
Weinstein CL and Petersen GM: Germline BRCA2 gene mutations in
patients with apparently sporadic pancreatic carcinomas. Cancer
Res. 56:5360–5364. 1996.PubMed/NCBI
|
|
6
|
Huang L, Goodrow TL, Zhang S, Klein-Szanto
AJP, Chang H and Ruggeri BA: Deletion and mutation analyses of the
p16/MTS1 tumour suppressor gene in human ductal pancreatic cancer
reveals a higher frequency of abnormalities in tumor-derived cell
lines than in primary ductal adenocarcinomas. Cancer Res.
56:1137–1141. 1996.
|
|
7
|
Moskaluk CA, Hruban RH and Kern SE: P16
and K-ras gene mutations in the intraductal precursors of human
pancreatic adenocarcinoma. Cancer Res. 57:2140–2143.
1997.PubMed/NCBI
|
|
8
|
Rozenblum E, Schutte M, Goggins M, Hahn
SA, Panzer S and Zaurak M: Tumor-suppressive pathways in pancreatic
carcinoma. Cancer Res. 57:1731–1734. 1997.PubMed/NCBI
|
|
9
|
Kawesha A, Chaneh P, Andren-Sandberg A,
Ograed D, Skar R and Dawiskiba S: K-ras oncogene subtype mutations
are associated with survival but not expression of p53, p16INK4A,
p21WAF-1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic
ductal adenocarcinoma. Int J Cancer. 89:469–474. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suzuki T and Takano Y: Comparative
immunohistochemical studies of p53 and proliferating cell nuclear
antigen expression and argyrophilic nucleoral organizer regions in
pancreatic duct cell carcinomas. Jpn J Cancer Res. 84:1072–1077.
1993. View Article : Google Scholar
|
|
11
|
Zhang SY, Ruggeri B, Agarwal P, Sorling
AF, Obara T and Ura H: Immunohistochemical analysis of p53
expression in human pancreatic carcinomas. Arch Pathol Lab Med.
118:150–154. 1994.PubMed/NCBI
|
|
12
|
Dergham ST, Dugan MC, Kucway R, Du W,
Kamarauskiene DS and Vaitkevicius VK: Prevalence and clinical
significance of combined K-ras mutation and p53 aberration in
pancreatic adenocarcinoma. Int J Pancreat. 21:127–143.
1997.PubMed/NCBI
|
|
13
|
Ruggeri BA, Huang L, Berger D, Chang H,
Klein-Szanto AJ and Goodrow T: Molecular pathology of primary and
metastatic ductal pancreatic lesions. Cancer. 79:700–716. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gansauge F, Gansauge S, Schmidt E, Muller
J and Beger HG: Prognostic significance of molecular alterations in
human pancreatic carcinoma – an immunohistological study.
Langenbecks Arch Surg. 383:152–155. 1998.
|
|
15
|
Yokoyama M, Yamanaka Y, Friess H, Buchler
M and Murray K: P53 expression in human pancreatic cancer
correlates with enhanced biological aggressiveness. Anticancer Res.
14:2477–2483. 1997.PubMed/NCBI
|
|
16
|
Jeong J, Park YN, Park JS, Yoon DS, Chi HS
and Kim BR: Clinical significance p16 protein expression loss and
aberrant p53 protein expression in pancreatic cancer. Yonsei Med J.
46:519–525. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dergham S, Dugan M, Joshi U, Chen Y, Du W,
Smith D, Arlauskas P, Crissman J, Vaitkevicius V and Sarkar F: The
clinical significance of p21 WAF1/CIP-1 and p53 expression in
pancreatic adenocarcinoma. Cancer. 80:372–381. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Molina MA, Sitja-Arnau M, Lemoine MG,
Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression
in human pancreatic carcinomas and cell lines: growth inhibition by
nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362.
1999.PubMed/NCBI
|
|
19
|
Kokawa A, Kondo H, Gotoda T, Ono H, Saito
D, Nakadaira S, Kosuge T and Yoshida S: Increased expression of
cyclooxigenase-2 in human pancreatic neoplasms and potential for
chemoprevention by cyclooxygenase inhibitors. Cancer. 91:333–338.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okami J, Yamamoto H, Fujiwara Y, Tsujie M,
Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa
O, Sakon M, Matsuura N, Nakamori S and Monden M: Overexpression of
cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res.
5:2018–2024. 1999.PubMed/NCBI
|
|
21
|
Koshiba T, Hosotani R, Miyamoto Y, Wada M,
Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R and Imamura M:
Immunohistochemical analysis of cyclooxygenase-2 expression in
pancreatic tumors. Int J Pancreatol. 26:69–76. 1999. View Article : Google Scholar
|
|
22
|
Williams TM, Weiner DB, Greene MI and
Maguire HC: Expression of erbB-2 in human pancreatic
adenocarcinoma. Pathobiology. 59:46–52. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Day DJ, Di Giuseppe JA and Yeo C:
Immunohistochemical evaluation of Her-2/neu expression in
pancreatic adenocarcinoma and pancreatic intraepithelial neoplams.
Hum Pathol. 27:119–124. 1996. View Article : Google Scholar
|
|
24
|
Hall PA, Hughes CM, Staddon SL, Richman
PI, Gullick WJ and Lemoine NR: The c-erbB-2 proto-oncogene in human
pancreatic cancer. J Pathol. 161:195–200. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamanaka Y, Friess H and Kobrin MS:
Overexpression of Her2/neu oncogene in human pancreatic carcinoma.
Human Pathol. 24:1127–1134. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dugan MC, Dergham ST and Kucway R:
Her-2/neu expression in pancreatic adenocarcinoma: relation to
tumour differentiation and survival. Pancreas. 14:229–236. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sirivatanauksorn V, Sirivatanauksorn Y and
Lemoine NR: Molecular pattern of ductal pancreatic cancer.
Langenbecks Arch Surg. 383:105–115. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lemoine NR, Hughes CM and Barton CM: The
epidermal growth factor receptor in human pancreatic cancer. J
Pathol. 166:7–12. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kioppel G, Maillet B and Schewere K:
Immunocytochemical detection of epidermal growth factor receptor
(EGFr) and transferrin receptor (TR) on normal, inflamed and
neoplastic pancreatic tissue. Pancreas. 4:6231989.
|
|
30
|
Uegaki K, Nio Y and Inoue Y:
Clinicopathological significance of epidermal growth factor and its
receptor in human pancreatic cancer. Anticancer Res. 17:3841–3848.
1997.PubMed/NCBI
|
|
31
|
Sterm DF and Kamps MP: EGF-stimulated
tyrosine phos-phorylation of p185neu a potential model of receptor
interactions. EMBO J. 7:995–1001. 1988.PubMed/NCBI
|
|
32
|
Kokai Y, Myers JN and Wada T: Synergistic
interaction of p185neu and EGF receptor leads to transformation of
rodent fibroblasts. Cell. 58:287–292. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Millauer B, Wizigmann-Voss S and Schunürch
H: High affinity VEGF binding and developmental expression suggest
Flk-1 as a major regulator of vasculogenesis and angiogenesis.
Cell. 72:835–846. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ferrara N and Henzel WJ: Pituitary
follicular cells secrete a novel heparin-binding growth factor
specific for vascular endothelial cells. Biochem Biophys Res
Commun. 161:851–858. 1989. View Article : Google Scholar
|
|
35
|
Gospodarowicz D and Lau K: Pituitary
follicular cells secrete both vascular endothelial growth factor
and follistatin. Biochem Biophys Res Commun. 165:292–298. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Vries C, Escobedo JA and Ueno H: The
fms-like tyrosine kinase, a receptor for vascular endothelial
growth factor. Science. 255:989–991. 1992.
|
|
37
|
Terman BI, Dougher-Vermazen M and Carrion
ME: Identification of KDR tyrosine kinase as a receptor for
vascular endothelial cell growth factor. Biochem Biophys Res
Commun. 187:1579–1586. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen H, Chedotal A and He Z: Neuropilin-2
a novel member of the neuropilin family, is a high affinity
receptor for the semaphorins Sema E and Sema IV but not Sema III.
Neuron. 19:547–559. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brown JM and Giaccia AJ: The unique
physiology of solid tumors. Opportunities (and problems) for cancer
therapy. Cancer Res. 58:1408–1416. 1998.PubMed/NCBI
|
|
40
|
Itakura J, Ishiwata T and Friess H:
Enhanced expression of vascular endothelial growth factor in human
pancreatic cancer correlates with local disease progression. Clin
Cancer Res. 3:1309–1316. 1997.PubMed/NCBI
|
|
41
|
Seo Y, Baba H, Fukuda T, Takashima M and
Sugimachi K: High expression of vascular endothelial growth factor
is associated with liver metastasis and poor prognosis for patients
with ductal pancreatic adenocarcinoma. Cancer. 88:2239–2245. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ellis LM, Takahashi Y, Fenoglio CJ, Cleary
KR, Bucana CD and Evans DB: Vessel counts and vascular endothelial
growth factor expression in pancreatic adenocarcinoma. Eur J
Cancer. 34:337–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fujimoto K, Hosotani R and Wada M:
Expression of two angiogenic factors, vascular endothelial growth
factor and platelet-derived endothelial cell growth factor in human
pancreatic cancer, and its relationship to angiogenesis. Eur J
Cancer. 34:1439–1447. 1998. View Article : Google Scholar
|
|
44
|
Buchler P, Peber HA, Buchler MW, Friess H
and Hines OJ: VEGF-RII influences the prognosis of pancreatic
cancer. Ann Surg. 236:738–749. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chung G, Yoon H, Zerkowsi M, Ghosh S,
Thomas L, Harigopal M, Charette L, Salem R, Camp R, Rimm D and
Burtness B: Vascular endothelial growth factor, FLT-1, and FLK-1
analysis in pancreatic cancer tissue microarray. Cancer.
106:1677–1684. 2006. View Article : Google Scholar : PubMed/NCBI
|
